Discover and read the best of Twitter Threads about #justpublished
Most recents (11)
#JustPublished!
A joint #ECDC - @EMA_News statement on updating #COVID19 vaccines composition for new #SARSCoV2 virus variants.
Read full here:
bit.ly/42wARAa
A joint #ECDC - @EMA_News statement on updating #COVID19 vaccines composition for new #SARSCoV2 virus variants.
Read full here:
bit.ly/42wARAa
#JustPublished!
Autumn #vaccination campaigns focused on older age groups and other high-risk populations are key to decrease impact of #COVID19.
Read full report: bit.ly/3ZJgEWk
Press release: bit.ly/3MdQjwJ
Autumn #vaccination campaigns focused on older age groups and other high-risk populations are key to decrease impact of #COVID19.
Read full report: bit.ly/3ZJgEWk
Press release: bit.ly/3MdQjwJ
To decrease the impact of #COVID19 hospitalisations and mortality, countries should plan for a continued roll-out of #COVID19vaccines.
Efforts should focus on protecting older adults & other vulnerable groups, such as those with underlying comorbidities & the immunocompromised.
Efforts should focus on protecting older adults & other vulnerable groups, such as those with underlying comorbidities & the immunocompromised.
#JustPublished!
Threat Assessment Brief: Implications for the EU/EEA of the spread of the #SARSCoV2 #Omicron XBB.1.5 sub-lineage.
Overall level of risk is low for the EU/EEA general population; moderate to high for vulnerable individuals.
Read:
bit.ly/XBB15TAB
#COVID19
Threat Assessment Brief: Implications for the EU/EEA of the spread of the #SARSCoV2 #Omicron XBB.1.5 sub-lineage.
Overall level of risk is low for the EU/EEA general population; moderate to high for vulnerable individuals.
Read:
bit.ly/XBB15TAB
#COVID19
Mathematical modelling indicates that #XBB15 could become dominant in the EU/EEA after 1-2 months, given the current low proportions reported in the EU/EEA & its estimated growth rate.
No signals of increased severity of XBB.1.5 compared to circulating omicron sub-lineages.
No signals of increased severity of XBB.1.5 compared to circulating omicron sub-lineages.
The proportion of XBB.1.5 in EU/EEA was lower than 2.5% for the final 2 weeks of '22 (the most recent period where variant proportions at this low level can be accurately estimated).
In the US, #XBB15 is currently spreading 12% faster than other variants.
bit.ly/XBB15TAB
In the US, #XBB15 is currently spreading 12% faster than other variants.
bit.ly/XBB15TAB
#JustPublished!
Increase in Invasive Group A streptococcal infections among children in Europe, including fatalities .
Full press release:
ecdc.europa.eu/en/news-events…
#StrepA #iGAS
Increase in Invasive Group A streptococcal infections among children in Europe, including fatalities .
Full press release:
ecdc.europa.eu/en/news-events…
#StrepA #iGAS
A number of European countries (IE, FR, NL, ES, SE and UK) indicate an increase seen during 2022, particularly since September, in the number of cases of invasive Group A Streptococcus (#iGAS) disease among children less than ten years of age.
#StrepA
#StrepA
During the same period, several deaths associated with #iGAS in children less than 10 years of age have also been reported. The increase has been several-fold higher than pre-pandemic levels for the equivalent period of time.
Read more:
ecdc.europa.eu/en/news-events…
#StrepA
Read more:
ecdc.europa.eu/en/news-events…
#StrepA
#JustPublished!
Spread of the #SARSCoV2 #Omicron variant sub-lineage BQ.1 in the EU/EEA.
BQ.1, including its sub-lineages, has been designated as Variant of Interest (#VOI) by ECDC as of 20 October 2022.
Full report: bit.ly/3VMLay0
Spread of the #SARSCoV2 #Omicron variant sub-lineage BQ.1 in the EU/EEA.
BQ.1, including its sub-lineages, has been designated as Variant of Interest (#VOI) by ECDC as of 20 October 2022.
Full report: bit.ly/3VMLay0
Based on modelling estimates, it is expected that by mid-November to beginning of December 2022, more than 50% of #SARSCoV2 infections will be due to BQ.1/BQ.1.1.
That level is expected to rise by the beginning of 2023, to more than 80%.
bit.ly/3VMLay0
#Omicron #BQ1
That level is expected to rise by the beginning of 2023, to more than 80%.
bit.ly/3VMLay0
#Omicron #BQ1
[1/3] What happens to AYA cancer survivors' wellbeing over time? Our new paper #justpublished reviews longitudinal studies to better understand these outcomes & help AYAs reach their full potential in life 💪 @NatalieKB8 @CanteenAus #AYAcancer onlinelibrary.wiley.com/doi/10.1002/po…
[2/3] Longitudinal studies are important for understanding how outcomes change over time. This global review identifies a wide range of outcomes important to AYA cancer survivors that have been studied longitudinally 👇 onlinelibrary.wiley.com/doi/10.1002/po…
[3/3] Some studies found improvements over time, others identified very little progress for a significant number of AYAs, indicating need for greater understanding & intervention 👇onlinelibrary.wiley.com/doi/10.1002/po…
#JustPublished!
@EMA_News and @ECDC_EU recommendations on "mix and match" vaccination courses and boosters.
Read full text here: bit.ly/3pDe6tb
@EMA_News and @ECDC_EU recommendations on "mix and match" vaccination courses and boosters.
Read full text here: bit.ly/3pDe6tb
Vaccines are continuing to prevent many millions of EU citizens from becoming very ill or dying and figures show that numbers of hospitalisations and deaths remain lowest in those Member States with the highest vaccination rates.
#COVID19 #VaccinesSaveLives #VaccinesWork
#COVID19 #VaccinesSaveLives #VaccinesWork
Due to a raise in #COVID19 infections and hospitalisations, we urge all EU citizens to get fully vaccinated and to adhere to recent recommendations on booster vaccination for #COVID19.
Recommendations on booster doses in our latest Rapid Risk Assessment: bit.ly/RRACOVID17
Recommendations on booster doses in our latest Rapid Risk Assessment: bit.ly/RRACOVID17
#JustPublished!
Interim public health considerations for the provision of additional #COVID19 vaccine doses.
Read full report here: bit.ly/ECDCBoosterDoc
Interim public health considerations for the provision of additional #COVID19 vaccine doses.
Read full report here: bit.ly/ECDCBoosterDoc
Providing all eligible individuals with the recommended dose regimen should remain the current
priority for #COVID19 vaccination programmes in the EU/EEA.
All vaccines authorised in the EU/EEA are highly protective against COVID19 related hospitalisation, severe disease & death.
priority for #COVID19 vaccination programmes in the EU/EEA.
All vaccines authorised in the EU/EEA are highly protective against COVID19 related hospitalisation, severe disease & death.
Administering an additional vaccine dose to people who may experience a limited response to the primary #COVID19 vaccination, such as some categories
of immunocompromised individuals, should already be considered now.
bit.ly/ECDCBoosterDoc
of immunocompromised individuals, should already be considered now.
bit.ly/ECDCBoosterDoc
#JustPublished:
Joint #ECDC, @EFSA_EU and #EURL Lm report: European Listeria typing exercise (ELiTE).
A cross-sectorial study identifies strong link between human #listeriosis clusters and ready-to-eat fish products.
Full text: bit.ly/3d5XzYn
Joint #ECDC, @EFSA_EU and #EURL Lm report: European Listeria typing exercise (ELiTE).
A cross-sectorial study identifies strong link between human #listeriosis clusters and ready-to-eat fish products.
Full text: bit.ly/3d5XzYn
#Listeriosis is a foodborne disease caused by L. monocytogenes bacteria. After ingestion via contaminated food, it can cause severe, life-threatening disease, often manifested as #septicaemia and/or #meningitis.
The severe disease happens particularly among elderly & immunocompromised people. It also may result in complications related to pregnancy.
ecdc.europa.eu/en/news-events…
ecdc.europa.eu/en/news-events…
#JustPublished:
Considerations on the use of #COVID19 self-tests in the EU/EEA.
Full text: bit.ly/30UZx8h
Considerations on the use of #COVID19 self-tests in the EU/EEA.
Full text: bit.ly/30UZx8h
Rapid antigen detection tests (#RADTs) that can be used as self-tests to detect #SARSCoV2 are becoming increasingly available on the EU/EEA markets.
These tests require individuals to collect a specimen, conduct a test and interpret the results by themselves.
These tests require individuals to collect a specimen, conduct a test and interpret the results by themselves.
At the time of writing this document, there were only a few #RADTs available for self-testing, and there was none CE-marked on the EU market in compliance with Directive 98/79/EC.
Risk assessment, latest news on confirmed cases, #preparadness checklist, geographical distribution and information on coronaviruses.
Find all relevant latest news on the outbreak of the #NovelCoronavirus #nCoV2019 on our dedicated page.
Info ➡️ bit.ly/nCoV2019
Find all relevant latest news on the outbreak of the #NovelCoronavirus #nCoV2019 on our dedicated page.
Info ➡️ bit.ly/nCoV2019
#RiskAssessment 22.01
• potential impact of #nCoV2019 outbreaks is high;
• further global spread is likely;
• moderate likelihood of infection for EU/EEA travellers visiting #Wuhan;
• moderate likelihood of detecting cases imported into EU/EEA;
Report: bit.ly/2urGsxe
• potential impact of #nCoV2019 outbreaks is high;
• further global spread is likely;
• moderate likelihood of infection for EU/EEA travellers visiting #Wuhan;
• moderate likelihood of detecting cases imported into EU/EEA;
Report: bit.ly/2urGsxe
@WHO @WHO_Europe @ECDC_EU @EU_Health @EU_Commission Daily update of the #nCoV2019 situation - 24.01
• 897 lab-confirmed cases
• 26 fatalities
• imported cases in: #HongKong, #Macau, #Taiwan, #Thailand, #Japan, #SouthKorea, the #US, #Singapore and #Vietnam
More: bit.ly/nCoV2019
• 897 lab-confirmed cases
• 26 fatalities
• imported cases in: #HongKong, #Macau, #Taiwan, #Thailand, #Japan, #SouthKorea, the #US, #Singapore and #Vietnam
More: bit.ly/nCoV2019
